<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367080</url>
  </required_header>
  <id_info>
    <org_study_id>DWETR-I-1</org_study_id>
    <nct_id>NCT01367080</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Pharmacokinetic Profiles of Etravil® Tablet 10mg and Etravil® Tablet 25mg</brief_title>
  <acronym>DWETR</acronym>
  <official_title>Clinical Trials to Compare the Pharmacokinetics Profile of Etravil®(Amitriptyline Hydrochloride) Tablet 10mg and Etravil®(Amitriptyline Hydrochloride) Tablet 25mg After a Single Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong Wha Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dong Wha Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics of single oral dose of Amitriptyline hydrochloride
      film-coated tablet 10mg &amp; 25mg
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, Single dose, 2-way crossover, Open Study to compare the pharmacokinetics profile
      of Etravil®(Amitriptyline Hydrochloride) Tablet 10mg and Etravil®(Amitriptyline
      Hydrochloride) Tablet 25mg after a single oral administration in healthy male volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast and AUCinf</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Area Under the Plasma concentration-time curve from time Zero to Infinity(AUCinf) and Area Under the Plasma concentration-time curve from time Zero to last time(AUClast) of Amitryptiline in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Maximum Concentration(Cmax) of amitryptyline in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Time for Maximum Concentration(Tmax) of Amitryptyline in Plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Terminal half-time(t1/2) of Amitryptyline in Plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Depression</condition>
  <condition>Depressive State</condition>
  <condition>Enuresis</condition>
  <arm_group>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st administration - DWETR10
2nd administration - DWETR25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st administration - DWETR25
2nd administration - DWETR10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWETR10</intervention_name>
    <description>Amitriptyline hydrochloride 10mg(DWETR10) single dose</description>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_label>B Group</arm_group_label>
    <other_name>Etravil 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWETR25</intervention_name>
    <description>Amitriptyline hydrochloride 25mg(DWETR25) single dose</description>
    <arm_group_label>A Group</arm_group_label>
    <arm_group_label>B Group</arm_group_label>
    <other_name>Etravil 25mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a healthy adult male within the range of 19 to 50 years old at the time of screening

          -  one with weight of more than 55kg, in the range of IBW 20%

               -  Ideal Body Weight(IBW)(kg)={height(cm)-100}*0.9

          -  one who understood completely about this study after the detailed explanation is
             given, decided to volunteer and gave written informed consent to participate in study
             in compliance with the requirement of the entire protocol.

        Exclusion Criteria:

          -  one with clinically significant disease in liver, kidney, nerve system, respiratory
             system, endocrine system, blood, tumor, urinary system, cardiovascular system, mental
             disease or with medical history

          -  one with glaucoma

          -  one with disorders of micturition include benign prostatic hyperplasia

          -  one with gastrointestinal disease or with gastrointestinal surgical history which can
             affect the absorption of the investigational drug.

          -  one who is allergic or has clinically significant allergic history to the study drug,
             components or tricyclic antidepressants(TCA)

          -  one who shows the following result in vital sign: hypotension(systolic pressure ≤
             100mmHg or diastolic pressure ≤ 65mmHg) or hypertension(systolic pressure ≥ 150mmHg or
             diastolic pressure ≥ 95mmHg)

          -  one who has drug abuse history

          -  one who has taken any prescribed drugs, herbal agents or crude drugs within 2 weeks
             before study drug administration, or who has taken any over-the-counter (OTC) drugs or
             vitamins (Investigators will determine his eligibility by considering the effect of
             the drug on his safety or pharmacokinetic results in case other inclusion/exclusion
             criteria is satisfied.)

          -  one who has participated in other clinical study within 2 months before study drug
             administration

          -  one who donated whole blood within 2 months or component blood within 1 month or who
             are donated within 1 month before the treatment

          -  one who drank Over 21 units/week of alcohol(1 unit = 10g of pure alcohol) or subjects
             who would not be able to stop drinking alcohol during the hospitalization

          -  one who are heavy smoker more than 10 cigarettes/day within 3 months prior to
             screening or subjects who would not be able to stop smoking during the hospitalization

          -  one who had a beverage containing caffeine, drank alcohol, or smoked within 48hrs
             before the hospitalization or who had a beverage containing grapefruits during the
             hospitalization

          -  one with clinically significant observations considered as unsuitable based on medical
             judgment by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital.</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeollabuk-do</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2011</study_first_posted>
  <results_first_submitted>February 20, 2013</results_first_submitted>
  <results_first_submitted_qc>August 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2014</results_first_posted>
  <last_update_submitted>August 6, 2014</last_update_submitted>
  <last_update_submitted_qc>August 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Amitriptyline, perphenazine drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from a specialty clinic at a hospital, Korea between July 2011 and August 2011</recruitment_details>
      <pre_assignment_details>15 participants recruited ; 12 screened, 3 excluded (2 did not meet inclusion criteria and 1 refused participation)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A Group</title>
          <description>Etravil tablet 10mg once daily in first intervention period and Etravil tablet 25mg once daily in second intervention period (10days washout period, Intervention period : 1day)</description>
        </group>
        <group group_id="P2">
          <title>B Group</title>
          <description>Etravil tablet 25mg once daily in first intervention period and Etravil tablet 10mg once daily in second intervention period (10days washout period, Intervention period : 1day)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>1st Administration</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2nd Administration</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A Group</title>
          <description>Etravil tablet 10mg once daily in first intervention period and Etravil tablet 25mg once daily in second intervention period (10days washout period, Intervention period : 1day)</description>
        </group>
        <group group_id="B2">
          <title>B Group</title>
          <description>Etravil tablet 25mg once daily in first intervention period and Etravil tablet 10mg once daily in second intervention period (10days washout period, Intervention period : 1day)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.2" spread="2.1"/>
                    <measurement group_id="B2" value="21.2" spread="2.1"/>
                    <measurement group_id="B3" value="21.7" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUClast and AUCinf</title>
        <description>Area Under the Plasma concentration-time curve from time Zero to Infinity(AUCinf) and Area Under the Plasma concentration-time curve from time Zero to last time(AUClast) of Amitryptiline in plasma</description>
        <time_frame>Up to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etravil 10mg Group</title>
            <description>Amitryptiline Hydrochloride 10mg administration Group</description>
          </group>
          <group group_id="O2">
            <title>Etravil 25mg Group</title>
            <description>Amitryptiline hydrochloride 25mg administration Group</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast and AUCinf</title>
          <description>Area Under the Plasma concentration-time curve from time Zero to Infinity(AUCinf) and Area Under the Plasma concentration-time curve from time Zero to last time(AUClast) of Amitryptiline in plasma</description>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUClast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.35" spread="25.88"/>
                    <measurement group_id="O2" value="260.68" spread="111.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCinf</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.74" spread="37.80"/>
                    <measurement group_id="O2" value="296.87" spread="124.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Maximum Concentration(Cmax) of amitryptyline in plasma</description>
        <time_frame>Up to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etravil 10mg Group</title>
            <description>Amitryptiline Hydrochloride 10mg Administration Group</description>
          </group>
          <group group_id="O2">
            <title>Etravil 25mg Group</title>
            <description>Amitryptiline Hydrochloride 25mg Administration Group</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum Concentration(Cmax) of amitryptyline in plasma</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.96" spread="1.40"/>
                    <measurement group_id="O2" value="17.69" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Time for Maximum Concentration(Tmax) of Amitryptyline in Plasma</description>
        <time_frame>Up to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etravil 10mg Group</title>
            <description>Amitryptiline Hydrochloride 10mg Administration Group</description>
          </group>
          <group group_id="O2">
            <title>Etravil 25mg Group</title>
            <description>Amitryptiline Hydrochloride 25mg Administration Group</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time for Maximum Concentration(Tmax) of Amitryptyline in Plasma</description>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="0.90"/>
                    <measurement group_id="O2" value="3.13" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2</title>
        <description>Terminal half-time(t1/2) of Amitryptyline in Plasma</description>
        <time_frame>Up to 72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etravil 10mg Group</title>
            <description>Amitryptiline Hydrochloride 10mg Administration Group</description>
          </group>
          <group group_id="O2">
            <title>Etravil 25mg Group</title>
            <description>Amitryptiline Hydrochloride 25mg Administration Group</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>Terminal half-time(t1/2) of Amitryptyline in Plasma</description>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.47" spread="5.64"/>
                    <measurement group_id="O2" value="24.79" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>About a month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Etravil 10mg Group</title>
          <description>Amitryptyline hydrochloride 10mg administration Group</description>
        </group>
        <group group_id="E2">
          <title>Etravil 25mg Group</title>
          <description>Amitryptyline hydrochloride 25mg administration Group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>When collecting blood samples, few subjects were drawn blood later than that stated in protocol for about 1 ~ 2 minutes where results may not be effected.
One of the subjects came in late for Post-study visit for about 4~6 days.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cheol-Hee Lim. Clinical Research Manager (CRM)</name_or_title>
      <organization>Dong Wha Pharm. Co. Ltd.</organization>
      <phone>+82-2-2021-9300 ext 551</phone>
      <email>cheolhee.lim@dong-wha.co.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

